openPR Logo
Press release

Dementia begins in the mid-40s - early detection crucial

07-10-2019 11:24 AM CET | Health & Medicine

Press release from: DST

Dementia begins in the mid-40s - early detection crucial

We know today that those who will probably be demented in 15 to 20 years are already experiencing their first brain changes today. In other words, in many people it is already clear at the age of 40 to 50 whether they start to develop dementia. Fortunately, our brain can compensate individual deficits so well for 15 to 20 years that the affected person and the environment do not notice them initially.

When the symptoms then become obvious at an advanced age, it is actually already too late, because there are still no effective medicines against dementia - however, the right active substances may actually be investigated, but at the wrong time, i.e. too late in the disease process.

At the same time, the question arises as to whether early detection in dementia makes any sense at all. Imagine you are sitting in a ship that is sinking - wouldn't you want a life jacket and a place in a lifeboat? In other words, when non-modifiable risks materialize (ship goes under), people intuitively draw their full attention to the modifiable risk factors – putting on a life jacket and getting into a life boat - which otherwise hardly anyone would do. The same with dementia - recognizing an existing risk motivates most people to actively reduce this risk through modifiable risk factors.

An early diagnosis with the earliest possible intervention is therefore crucial for the best possible treatment. This is also what more than 90% of patients wish for. In some countries (e.g., USA, Canada, Great Britain), dementia has long been an integral part of regular check-ups. Over the last few years, these countries have seen a decrease in the incidence of new dementia patients and, consequently, a decrease in the number of nursing home places needed - a win-win situation for those concerned as well as for healthcare costs.

The App DST - Dementia Screening Test is an innovative digital solution for the early detection and follow-up of dementia. The 5 short subtests of the DST specifically cover the brain functions that are affected by dementia at an early stage, thus enabling early detection 18 years and more before the first symptoms. Compared to the classic "paper and pen" tests, the sensitivity is also higher (DST > 96%, MMSE 81%) and the correct answers cannot be "learned" because the App automatically changes the tasks slightly from test to test. In addition, a progress control is integrated and the testing is significantly more cost-effective, faster and burdens the everyday practice less than the classical tests conducted by healthcare professionals. Since its introduction at the beginning of 2019, the DST has thus received several awards, among others:

- Vision.A Award in Gold 2019, as the most innovative patient app
- Best Dementia app at Digimeda
- Best Dementia App at ORCHA
- Best Dementia App at iMedicalApps
- Detailed description and recommendation in Deutsches Ärzteblatt
- The only dementia app that has been recognized as a medical device

The test is completely anonymous, without complicated registration, and it can be performed fast and easy at home, in the waiting room or in the pharmacy, also by laypersons without special knowledge.

DST
Dr. S. Horn
Friedrichstr. 67
10117 Berlin, Germany

horn@demenz-test.com
www.demenz-test.com

The DST was developed by a team of physicians to enable early dementia detection. More about the Dementia Screening Test at: https://www.demenz-test.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dementia begins in the mid-40s - early detection crucial here

News-ID: 1800306 • Views: 222

More Releases from DST

12-19-2019 | Health & Medicine
DST
Dementia screening and prevention – hope or hype?
It is estimated that about 50% of dementia patients do not receive a formal diagnosis. And when the diagnosis is made, it often happens at a time when the disease is well advanced and brain damages are irreversible. A major reason for this is that systematic dementia screening and prevention programmes are not yet ready for implementation as large-scale public health interventions. A key reason for this is the desire
02-11-2019 | Health & Medicine
DST
Dementia test predicts disease 18 years before symptoms
• Multi-dimensional cognitive tests detect restrictions at least 18 years prior to clinical Dementia symptoms. • Good therapy options exist for this pre-symptomatic phase. It has been known for several years that cognitive tests can "predict" dementia 10-12 years prior to clinical symptoms - or more precisely: they can recognize initial limitations in people who are not clinically conspicuous / symptomatic in everyday life, but who are later diagnosed with dementia. The
01-08-2019 | Health & Medicine
DST
Early Dementia detection via App receives medical device status
- The DST (Dementia Screening Test) App has been recognized by Health Authorities as a Medical Device. - Early Dementia stages are reliably detected, before the brain damages become irreversible. - Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%). Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today, there is no effective therapy for advanced stages of dementia. Therefore, effective screening
12-11-2018 | Health & Medicine
DST
New App detects dementia risks early
• The App is certified as a Medical Device. • Early stages are reliably detected, before the brain damage becomes irreversible. • Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%). • Now available for free during pre-launch. Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today there is no effective therapy for advanced stages of dementia. Therefore, effective screening tests are needed to detect early stages

All 5 Releases


More Releases for Dementia

2nd International Conference on Dementia and Dementia Care
Breakthrough in Dementia Research and Care Event Name: 2nd International Conference on Dementia and Dementia Care (Dementia 2019) Theme: Breakthrough in Dementia Research and Care Aim and Scope: Dementia is an umbrella term used to describe a set of symptoms that occur when the brain is affected by disease. There’s currently no cure and no treatment that slows or stops its progression, but there are things you can do to help reduce the
11th International Conference on Vascular Dementia
Can We Cure Dementia, Vascular Dementia and Alzheimer's disease? It’s our pleasure to invite all the participants from all over the world to attend the 11th International Conference on Vascular Dementia which is held during February 15-16, 2019 Amsterdam| Netherlands. Vascular Dementia conference will assemble illustrious speakers, Researchers, Nobel laureates, Neurologists, and Neuroscience researchers from both academic and health care professionals will join this event to discuss their views and research. The
2nd International conference on Dementia and Dementia Care
Breakthrough in Dementia Research and Care Event Name: 2nd International Conference on Dementia and Dementia Care (Dementia 2019) Theme: Breakthrough in Dementia Research and Care Aim and Scope: Dementia is an umbrella term used to describe a set of symptoms that occur when the brain is affected by disease. There’s currently no cure and no treatment that slows or stops its progression, but there are things you can do to help reduce the
Global Alzheimer’s disease, Dementia and Ageing Awareness
Lexis brings in a new spin on conferences by presenting the latest scientific improvements in the fields of Neurology and Neuroscience. Zurich is all set for an amazing event as LEXIS proudly presents the “Global Alzheimers, Dementia and Ageing Awareness” slated on July 17-18, 2019 at Zurich, Switzerland. The theme of the conference is “Global Voice and Awareness on Alzheimers Disease and Dementia Care”. Avenue Roger VAndendriessche, 18 at 1150 BRUSSELS Avenue
Dementia Market -Pipeline Review, H1 2018: MarketResearchReports.biz
"The Latest Research Report Dementia-Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H1 2018, provides an overview of the Dementia (Central Nervous System) pipeline landscape. Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with
Dementia - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Dementia - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape. Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with